Maxime Dely on Why Ethical Blood Donation Matters
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on Linkedin:
“Ethical Blood Donation vs. Economic Pressure
Isn’t it time we brought voluntary donation back to the center of the conversation?
In France, our transfusion model is built on a strong foundation: voluntary, anonymous, and unpaid donation.
A globally recognized ethical stance that puts solidarity above profit. But this model is under pressure.
The demand for blood products — especially plasma-derived medicines — is soaring. Some countries turn to commercial suppliers abroad. And the question arises: why not pay donors to meet demand? But what do we risk losing?
Trust. Between the donor and society. Between the patient and the healthcare system.
The day donation becomes a transaction, it loses part of its human value.
To protect this model, we need more than good intentions. We must adapt it to the times:
- Modernize our communication,
- Rethink social marketing,
- Speak to a new generation of donors, with their codes, values, and expectations.
Ethical donation is sustainable — if we give it the means to remain so.
This deserves more than a financial decision. It deserves a real public debate.”
Stay informed with Hemostasis Today.
-
Aug 13, 2025, 06:44Chokri Ben Lamine: Causes and Diagnostic Approach to PTT Prolongation
-
Aug 13, 2025, 05:41ISTH 2025 Recorded Sessions Now Available on ISTH Academy
-
Aug 13, 2025, 01:39Radoslaw Kaczmarek: Challenges Limiting Gene Therapy Use in Hemophilia
-
Aug 12, 2025, 20:03David McIntosh Urges WHO, the European Blood Alliance, the International Plasma and Fractionation Association to Stop Opposition to VRCD
-
Aug 12, 2025, 18:44Maxime Dely: Does Whole Blood Deserve a Greater Role in Modern Transfusion Medicine?
-
Aug 13, 2025, 06:13Pip Nicolson: Understanding VITT From COVID-19 Vaccines
-
Aug 13, 2025, 05:23Baseline Hemoglobin Predicts Outcomes in Acute VTE: Low Hb Linked to Higher Bleeding, Ischemia and Mortality Risk
-
Aug 13, 2025, 04:13Lindsey George on Gene Therapy Transforming Hemophilia Care
-
Aug 13, 2025, 02:26Case Report Alert: Basilar Artery Occlusion in IgA-APS
-
Aug 12, 2025, 20:23Behnood Bikdeli on Comparative Effectiveness Research Examples in Thrombosis
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 11, 2025, 05:16Andreas Calatzis: Any Information on Soviet Thrombelastographs?
-
Aug 9, 2025, 15:36NBCA: Blood Clot Survivor Runs 2025 NYC Marathon with Team Stop the Clot
-
Aug 8, 2025, 18:33Hemophilia Alliance during Tennessee Hemophilia and Bleeding Disorders Foundation Annual Meeting 2025
-
Aug 7, 2025, 14:49JAMA+AI Conversations: David Rhew's Journey from Clinical Practice to Technology Leadership
-
Aug 6, 2025, 16:47My Clot Story: Birth Control and A Life-threatening Pulmonary Embolism